Literature DB >> 30149923

Evaluation of Mass Vaccination Clinics in Response to a Serogroup B Meningococcal Disease Outbreak at a Large, Public University-Oregon, 2015.

Emily A Fisher1, Tasha Poissant2, Patrick Luedtke3, Richard Leman2, Collette Young2, Paul Cieslak2.   

Abstract

PURPOSE: Between January and May 2015, seven people at a large, public university developed invasive serogroup B meningococcal disease. One case was fatal. Attack rates were highest among freshmen and members of sororities, and fraternities (Greek organizations). Mass vaccination clinics using newly licensed serogroup B vaccine were held in March, May, and October 2015. No cases occurred after the second mass vaccination clinic.
METHODS: We surveyed vaccine recipients at each clinic from March to October 2015 to determine preferred methods for notification about vaccination clinics, assess motivations for attending, and evaluate the clinic attendee population.
RESULTS: Vaccination rates were low; 15% of undergraduates received one vaccine dose. An additional 11% received two doses of the three-dose MenB-FHbp series, and 4% completed a serogroup B meningococcal vaccine series at a mass vaccination clinic. University freshmen were 2.3 times as likely (confidence interval: 2.2-2.9) and Greek members 1.3 times as likely (confidence interval: 1.2-1.4) to attend a mass vaccination clinic as nonfreshmen or non-Greek members, respectively. Attendees reported e-mail as their preferred communication method (90%). Concerns about developing meningococcal disease (66%) and parental request (56%) were the most commonly cited motivations for attending a vaccination clinic.
CONCLUSIONS: The serogroup B meningococcal outbreak at this large, public university disproportionately affected freshmen and students affiliated with Greek organizations. Despite low overall vaccination rates, the vaccination campaign did reach the populations at risk. In future outbreaks at large universities, we recommend focusing vaccination efforts on specific at-risk populations to maximize vaccination of those most at risk for this deadly disease.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Meningococcal; Outbreak; Response; Serogroup B; Vaccine

Mesh:

Substances:

Year:  2018        PMID: 30149923     DOI: 10.1016/j.jadohealth.2018.03.018

Source DB:  PubMed          Journal:  J Adolesc Health        ISSN: 1054-139X            Impact factor:   5.012


  5 in total

1.  Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease.

Authors:  Elizabeth M La; Sandra E Talbird; Koren V Kanadanian; Liping Huang; Joel Fain; Amit Srivastava
Journal:  Hum Vaccin Immunother       Date:  2019-01-16       Impact factor: 3.452

2.  Best Practices for COVID-19 Mass Vaccination Clinics.

Authors:  Shima Shakory; Azza Eissa; Tara Kiran; Andrew D Pinto
Journal:  Ann Fam Med       Date:  2022 Mar-Apr       Impact factor: 5.166

3.  Increasing awareness and uptake of the MenB vaccine on a large university campus.

Authors:  Eric Richardson; Kathleen A Ryan; Robert M Lawrence; Christopher A Harle; Shivani M Desai; Melvin D Livingston; Amit Rawal; Stephanie A S Staras
Journal:  Hum Vaccin Immunother       Date:  2021-06-02       Impact factor: 4.526

4.  University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013-2018.

Authors:  Heidi M Soeters; Lucy A McNamara; Amy E Blain; Melissa Whaley; Jessica R MacNeil; Susan Hariri; Sarah A Mbaeyi
Journal:  Emerg Infect Dis       Date:  2019-03       Impact factor: 6.883

5.  Meningococcal Group B Vaccine For The Prevention Of Invasive Meningococcal Disease Caused By Neisseria meningitidis Serogroup B.

Authors:  Irene Rivero-Calle; Peter Francis Raguindin; Jose Gómez-Rial; Carmen Rodriguez-Tenreiro; Federico Martinón-Torres
Journal:  Infect Drug Resist       Date:  2019-10-09       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.